Award details

Novel biocatalytic reductions for synthesis of chiral amines

Reference	BB/D002826/1
Principal Investigator / Supervisor	Professor Gillian Stephens
Co-Investigators / Co-Supervisors	Dr Robin Curtis, Dr John Gardiner
Institution	The University of Manchester
Department	Chem Eng and Analytical Science
Funding type	Research
Value (£)	438,955
Status	Completed
Type	Research Grant
Start date	13/03/2006
End date	12/08/2010
Duration	53 months

Abstract

New enzymes will be developed for preparation of chiral amines. New reductases from anaerobic bacteria will be developed for reduction of C-C double bonds and aliphatic nitro groups. The enzymes will be purified and fully characterised, and the corresponding genes will be cloned in E. coli. The substrate ranges and stereoselectivities of the enzymes will be determined, along with their activities, substrate tolerance and stability. Recombinant production strains will be developed, incorporating gene knockouts to eliminate side reactions if required. In addition, metabolically engineered strains will be developed, incorporating nitroalkene reductase and aliphatic nitroreductase for direct conversion of nitroalkenes to enantiopure aminoalkanes. Initial studies will be done to indicate the best routes for industrial implementation of the new biocatalysts.

Summary

Chiral amines are used very widely as chemical intermediates to produce drug molecules. Chiral amines exist in more than one form, called enantiomers, and often only one of them is suitable for use in medicine. However, it is extremely difficult to produce the required enantiomer of many chiral amines by standard chemical techniques. It is much better to use enzymes to produce amines, because many enzymes produce pure enantiomers. However, there are still very few enzymes that are suitable for chiral amine production. In this project, we plan to develop new enzymes to produce chiral amines for drug manufacture. The enzymes are from bacteria that grow without oxygen(anaerobes). These bacteria have very unusual enzymes. The amine-producing enzymes that we have discovered catalyse a wide range of reactions that do not occur in other cells. The project will include purifying and characterising the enzymes. We shall also develop genetically engineered bacteria to use for amine manufacturing, because the anaerobes are not really suitable for use in industry. Ultimately, the new enzymes will make it possible to manufacture existing drugs much more cheaply. Furthermore, it should also become possible to produce new medicines that cannot be made at present.

Committee	Closed Committee - Engineering & Biological Systems (EBS)
Research Topics	Industrial Biotechnology, Microbiology, Synthetic Biology
Research Priority	X – Research Priority information not available
Research Initiative	X - not in an Initiative
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search